KOSDAQBiotech & Pharma083790

CG Invites

₩543▼ 22.43%2026-11-18 close
Market Cap
₩41.8B
Turnover
₩700M
Volume
1.2M
Shares out.
76.9M
PER
7.8×
PBR
0.5×
EPS
₩89
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue up, losses persist as reverse split nears

Revenue reached KRW 27.4 billion in 2025 and has risen for two straight years, but operating losses have continued for five consecutive quarters, making the shift to a profitable structure the central question.

  1. 1

    2025 revenue rose 277.6% to KRW 27.4 billion; the company cited growth in genomics-based services and small acquisitions consolidated into its accounts.

  2. 2

    The operating loss narrowed to KRW 23.8 billion in 2025 from KRW 38.8 billion in 2024, but the company has recorded losses in each year from 2022 to 2025.

  3. 3

    Q3 2026 revenue of KRW 4.98 billion rose 7.9% from the prior quarter but fell 18.8% year on year, and attributable net losses have persisted for three quarters.

  4. 4

    A bio-industry news report said cash and equivalents fell to KRW 2.5 billion at end-September 2026 from KRW 11.6 billion at end-2025.

  5. 5

    The board approved a 10-to-1 reverse stock split on November 17, 2026, with an extraordinary shareholders' meeting set for December 29, 2026; the execution of the China joint-venture licensing deal is the next item to watch.

02

Business structure

CG Invites began as a drug developer, but the growth engine behind its 2025 revenue is now its digital healthcare business.

The company attributed the 2025 revenue increase to genomics-based services linked to its digital healthcare infrastructure, small acquisitions that brought companies into consolidation, and lower selling, general and administrative expenses.

Its core platform, Invites Loop, uses artificial intelligence to analyze health data, assess disease risk, and connect health checkups, treatment, and aftercare. A Korean pharma news outlet reported that the 2025 growth was driven by digital healthcare and hot-pack and equipment businesses rather than drug development.

In drug development, the pancreatic cancer candidate CG-745 (ivaltinostat) is the key pipeline asset and is being developed through the U.S. subsidiary CGP. However, a legal dispute between the parent and CGP has reportedly all but cut off the sharing of research information.

R&D spending in 2025 was KRW 4.4 billion, down 60.9% from the prior year. In China, the company set up a Hong Kong joint venture, VIDW, in September 2026 and granted it exclusive rights to Invites Loop in mainland China, with a royalty of 5% of net sales.

Its customer base spans healthcare buyers such as hospitals, companies and insurers. Competition overlaps with genomics analytics firms and digital infrastructure providers that serve hospitals.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩6.1B-₩6.9B−112.4%
2025Q4₩12B-₩3.8B−31.6%
2026Q1₩4.3B-₩6.1B−142.3%
2026Q2₩4.6B-₩5.9B−127.3%
2026Q3₩5B-₩5.9B−118.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩38.6B-₩24.1B-₩25.6B−62.3%−13.6%66.8%
2023₩4.9B-₩30.9B-₩50B−633.6%−34.4%67.3%
2024₩7.3B-₩38.8B-₩51.5B−535.1%−52.3%115.6%
2025₩27.4B-₩23.8B-₩3.5B−86.7%−3.3%88.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue fell from KRW 38.6 billion in 2022 to KRW 4.88 billion in 2023 (down 87.4% year on year), then rose to KRW 7.25 billion in 2024 (up 48.7%) and KRW 27.4 billion in 2025 (up 277.6%), growing for two consecutive years from 2024 to 2025. 2022 was the largest year in the period and 2023 the smallest.

The operating loss widened from KRW 24.1 billion in 2022 to KRW 30.9 billion in 2023 and KRW 38.8 billion in 2024, then narrowed to KRW 23.8 billion in 2025; the company has posted losses for four consecutive years from 2022 to 2025.

The operating margin moved from -62.3% in 2022 to -633.6% in 2023 and -535.1% in 2024 before improving to -86.7% in 2025. In 2023, the loss stayed large while revenue collapsed, which drove the ratio sharply worse.

Attributable net loss was KRW 25.6 billion in 2022, KRW 50 billion in 2023, KRW 51.5 billion in 2024 and KRW 3.52 billion in 2025, while the net loss including non-controlling interests was KRW 12.5 billion in 2025, so the two figures differ.

The company said consolidated EBITDA improved from negative KRW 34.6 billion in 2024 to negative KRW 17 billion in 2025, in a press release. Quarterly revenue reached KRW 12 billion in Q4 2025, up 95.9% from the prior quarter, then fell to KRW 4.29 billion in Q1 2026 (down 64.3%).

It rose to KRW 4.61 billion in Q2 and KRW 4.98 billion in Q3 2026, two consecutive quarterly gains, but Q3 revenue was 18.8% lower than a year earlier. Operating losses were KRW 6.89 billion in Q3 2025, KRW 3.79 billion in Q4 2025, KRW 6.1 billion in Q1 2026, KRW 5.87 billion in Q2 and KRW 5.88 billion in Q3 2026.

The attributable net income of KRW 23.8 billion in Q4 2025 ran opposite to the operating loss, which suggests non-operating items had a large effect; the breakdown can be found in the non-operating income and expense notes of the periodic filings.

Attributable net losses followed at KRW 4.47 billion in Q1 2026, KRW 6.65 billion in Q2 and KRW 6.79 billion in Q3, three consecutive loss quarters. The sum of attributable net income over the last four quarters, KRW 5.85 billion, includes the Q4 2025 profit.

At end-2025, total equity was KRW 118.7 billion, of which KRW 105.2 billion belonged to controlling shareholders, and total liabilities were KRW 105.4 billion; the debt ratio fell from 115.6% in 2024 to 88.8% in 2025.

Operating cash flow was negative in all four years: KRW -24.4 billion in 2022, KRW -32.4 billion in 2023, KRW -25.9 billion in 2024 and KRW -17.4 billion in 2025.

05

Industry analysis

The market this company serves is AI-based digital healthcare and genomics analysis, a segment in an early expansion phase supported by demand for personalized health management. The company emphasizes that Invites Loop connects hospitals, companies and insurers.

In China, the VISTA group operates clinics that see tens of thousands of outpatients a year in Beijing and Shenzhen, along with more than 30 corporate medical facilities, and the company plans to use that network to enter the market.

Because the company still runs operating losses, the pace of expansion depends on its funding capacity. Within the sector, large players such as Samsung Biologics and Celltrion focus on large-scale manufacturing and exports, while Alteogen, HLB and LigaChem Biosciences center on platforms or drug pipelines.

CG Invites differs from these peers because its drug development share has shrunk while digital healthcare has grown. A Korean pharma news outlet reported concern that its identity as a first-generation drug developer is weakening.

On the regulatory side, rules on the collection and use of health data could affect the pace of business, and overseas operations would be subject to local rules.

06

Outlook

The company has said that AI healthcare and digital infrastructure businesses, including Invites Loop, will be reflected in its results in earnest from 2026. Q3 2026 revenue fell 18.8% year on year, so the timing of that reflection should be checked against quarterly results.

The China business began with a September 17, 2026 agreement with VISTA Clinic Limited to form the Hong Kong joint venture VIDW, followed by a licensing agreement announced on September 28 that grants exclusive mainland China rights to Invites Loop.

The royalty is 5% of net sales, and the technology valuation of about KRW 9.4 billion is an appraisal, not revenue. The company said it aims to use the China business as a standard model for expansion across Asia and global markets.

On the share side, the board approved on November 17, 2026 a 10-to-1 reverse split that raises the par value per share from KRW 500 to KRW 5,000. The extraordinary shareholders' meeting is set for December 29, 2026, and trading is scheduled to be suspended from January 28 to February 26, 2027.

The effective date for the new shares is January 30, 2027, with listing scheduled for March 2, 2027, and the company said the schedule could change through coordination with authorities.

The 2025 annual preliminary results were disclosed on February 11, 2026, so the 2026 annual preliminary results are likely to arrive around early 2027. The 2026 annual business report is due by the end of March 2027.

07

Valuation

PER
7.8×
PBR
0.5×
ROE
7.5%
EPS
₩89
BPS
₩1,335
Dividend per share
₩0

The price-to-book ratio sits below 1x, meaning the shares trade at a discount to book value attributable to controlling shareholders. For a company with continuing operating losses, however, how fast that book value is being eroded matters alongside the discount itself.

A price-to-earnings multiple can be calculated because attributable net income over the last four quarters is positive (KRW 5.85 billion), but that profit depends heavily on a single quarter, Q4 2025, so the multiple is sensitive to earnings swings.

Comparing with past multiple ranges is difficult, since multiples in periods of minimal earnings are hard to read as earnings-based signals. The dividend yield is effectively near zero, so shareholder return offers little to weigh in valuation.

A reverse split changes the share count and per-share price unit without changing the company's underlying value, and a Korean news report interpreted it as a step to avoid the new delisting rules for low-priced stocks.

Compared with larger listed peers, the current valuation rests more on assets and business value than on earnings-based multiples.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Expanding revenue base

Annual revenue rose from KRW 7.25 billion in 2024 to KRW 27.4 billion in 2025, growing for two consecutive years from 2024 to 2025. Genomics-based services and small acquisitions consolidated into the accounts, cited by the company as the reasons, expanded the top line.

According to a company press release, consolidated EBITDA also improved from negative KRW 34.6 billion in 2024 to negative KRW 17 billion in 2025. The company has said Invites Loop will be reflected in its results in earnest from 2026.

Narrowing losses and a changing cost base

The operating loss narrowed from KRW 38.8 billion in 2024 to KRW 23.8 billion in 2025, and the operating margin improved from -535.1% to -86.7%. The company said higher revenue is easing the burden of fixed costs such as personnel and operating expenses.

A decline in selling, general and administrative expenses in 2025 was also cited as a factor in the improvement. The debt ratio fell from 115.6% in 2024 to 88.8% in 2025.

China technology licensing and royalty structure

In September 2026, the company granted exclusive mainland China rights to Invites Loop through the Hong Kong joint venture VIDW. The deal provides a royalty of 5% of net sales, and the technology is valued at about KRW 9.4 billion.

That figure is an appraisal rather than revenue, so actual income will depend on performance in the local business. The company plans to enter the Chinese market using the medical, corporate and insurance network of the VISTA group.

09

Bear factors

Continuing quarterly losses

Operating losses for Q1 through Q3 2026 were KRW 6.1 billion, KRW 5.87 billion and KRW 5.88 billion, staying within a narrow band. Attributable net losses widened from KRW 4.47 billion in Q1 to KRW 6.79 billion in Q3, a three-quarter losing streak.

The KRW 5.85 billion sum of attributable net income over the last four quarters includes the KRW 23.8 billion profit of Q4 2025. Q3 2026 revenue fell 18.8% year on year.

Shrinking cash and funding pressure

A bio-industry news report said cash fell to KRW 2.5 billion at end-September 2026, about a quarter of the KRW 11.6 billion held at end-2025. Operating cash flow was negative in every year from 2022 to 2025, reaching negative KRW 17.4 billion in 2025.

Total borrowings peaked near KRW 93.1 billion at end-2024 and declined to about KRW 86.2 billion at end-September 2025, while total liabilities stood at KRW 105.4 billion at end-2025.

Uncertainty in the drug pipeline

R&D spending in 2025 was KRW 4.4 billion, down 60.9% from the prior year, and outsourced research fees fell 84.9%. The core candidate CG-745 is developed at the U.S. subsidiary CGP, and a report said research information sharing between the parent and the subsidiary has been cut off. Concern is growing that the company's identity as a drug developer is weakening.

10

Risk factors

Liquidity and funding

Cash fell to about KRW 2.5 billion at end-September 2026, and operating cash flow was negative in all four years. The debt ratio stood at 88.8% at end-2025, with total liabilities of KRW 105.4 billion.

If additional funding becomes necessary, rights offerings or borrowing terms could affect the shareholder base and interest burden.

Listing rules and share schedule

Staying below KRW 1,000 for an extended period raised the risk of falling under the new delisting rule for low-priced stocks, according to news reports. The company is responding with a 10-to-1 reverse split, with trading suspended from January 28 to February 26, 2027.

A KOSDAQ company faces a management-issue designation if its loss-before-tax ratio exceeds 50% in two of the last three business years. The company has said it will re-disclose if the schedule changes.

Business structure and governance

Income from the China joint venture depends on the royalty rate and local net sales, so the amount is uncertain until execution results appear. If the legal dispute over the U.S. subsidiary remains unresolved, the flow of information on the core pipeline stays restricted.

If the reflection of digital healthcare results in earnings is delayed, the loss-making structure could persist longer.

11

What to watch next

  1. December 2, 2026

    Record date for voting rights at the extraordinary shareholders' meeting on the 10-to-1 reverse split.

  2. December 29, 2026

    Extraordinary shareholders' meeting at the R&D center in Gangseo-gu, Seoul, where the amendment raising the par value from KRW 500 to KRW 5,000 is voted on.

  3. January 28 to February 26, 2027

    Scheduled trading suspension period. Together with the effective date for the new shares on January 30, 2027, this is where any schedule changes from coordination with authorities would appear.

  4. Around February 2027

    Expected timing of the Q4 and full-year 2026 preliminary results. The 2025 annual preliminary results were disclosed on February 11, 2026; the operating loss size and cash trend are the items to check.

  5. March 2, 2027 (scheduled listing of new shares)

    Scheduled listing date for the new shares after the consolidation. The share price that forms in the market after listing and the change in shares outstanding are the points to track. The 2026 annual business report is due by the end of March 2027.

12

Overall view

CG Invites' revenue rose 277.6% to KRW 27.4 billion in 2025 and grew for two consecutive years, so the scale of the top line has clearly expanded.

Operating and attributable net losses narrowed in 2025, but quarterly operating losses have stayed in a band of roughly KRW 5.8 billion to KRW 6.1 billion in 2026, so a shift in the profit structure is not yet backed by quarterly results.

The sum of attributable net income over the last four quarters is positive, but it rests on the KRW 23.8 billion profit of Q4 2025. The China joint venture and licensing deal are a new axis of expansion, but the KRW 9.4 billion technology valuation is not revenue.

With cash reportedly down to about KRW 2.5 billion at end-September 2026, funding is a key item to monitor. The reverse split, trading suspension and new-share listing run from December 2026 to March 2027.

Growth in revenue and narrower losses sit alongside shrinking cash and continuing losses on a comparable footing, so the operating loss size and cash flow in the next periodic report are the key checkpoints.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. biotimes.co.kr
  2. thebionews.net
  3. digitaltoday.co.kr
  4. pharm.edaily.co.kr
  5. dailypharm.com
  6. bloter.net
  7. fnnews.com
  8. bloter.net
  9. dealsite.co.kr
  10. thebionews.net
  11. news.nate.com
  12. kind.krx.co.kr
  13. judal.co.kr
  14. judal.co.kr
  15. judal.co.kr
  16. judal.co.kr
  17. prnewswire.com
  18. judal.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis